Verastem Inc
VSTM
Get informed when a big investor buys or sells
+ FollowMarket Cap$736.38M
Close$
$-6.09
166% downside
Current Fair Value
166% downsideOvervalued by 166% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $736.38 Million |
|---|---|
| Enterprise Value | $676.42 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.02 |
| Beta | 0.32 |
| Outstanding Shares | 100,116,000 |
Return
| Return on Equity | -405.51% |
|---|---|
| Return on Assets | -98.15% |
| Return on Invested Capital | -124.47% |
Valuation & Multiples
| P/E Ratio | -3.41 |
|---|---|
| PEG | -10.11 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 7.73 |
| Enterprise Value to EBIT | -4.23 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | 1.53 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.43
Average shareholder expectationRevenue Estimate
$22.88 M
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$-0.44
Average shareholder expectationRevenue Estimate
$28.98 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 2.6634▲ 261.80% |
|---|---|
| Total Calls | 191,300▼ 72.98% |
| Total Puts | 509,500▲ 1487.23% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 95.26%▲ 12.46% |
|---|---|
| Total Invested | $364.59M▼ 15.60% |
| Investors Holding | 167▲ 5.00% |
ESG Score
No data
About Verastem Inc
102 employees
CEO: Brian Stuglik Verastem, Inc. is an emerging biopharmaceutical firm dedicated to the discovery, development, and eventual commercialization of innovative therapies targeting various cancers. Central to its pipeline is VS-6766, an investigational compou...